All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Avelumab
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: 4D Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 08, 2021
Details:
4D pharma intends to commence a clinical trial in 2021 to evaluate BAVENCIO in combination with MRx0518 as a first-line maintenance therapy for locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Treosulfan,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Trecondi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Medexus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 02, 2021
Details:
Medac intends to leverage its strong, existing commercial infrastructure in the United States to address the underserved allo-HSCT market through its commercialization of treosulfan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Monjuvi(R)
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Tafasitamab is MorphoSys' CD19-directed antibody which was recently approved by the U.S. FDA in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LOXO 101
Therapeutic Area: Oncology Product Name: Vitrakvi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
In an expanded data set with a longer follow-up (cut-off July 15, 2019) of 175 patients (116 adult and 59 pediatric) with non-primary central nervous system (CNS) TRK fusion cancer, Vitrakvi demonstrated a durable, investigator-assessed overall response rate (ORR) of 78%.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Darolutamide
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2020
Details:
Men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Afatinib Dimaleate,Osimertinib
Therapeutic Area: Oncology Product Name: Gilotrif
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
Sequential Gilotrif® (afatinib) and osimertinib contributed to a median overall survival (OS) of nearly four years among U.S. patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer and the common resistance mutation, T790M.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Monjuvi
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2020
Details:
Monjuvi, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been approved under accelerated approval by the U.S. FDA based on overall response rate (ORR).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
